Basic information Safety Supplier Related

2-methoxyethyl 4-((4-(4-chlorophenoxy)-3,5-difluorophenyl)sulfonyl)-3-(hydroxycarbamoyl)piperazine-1-carboxylate

Basic information Safety Supplier Related

2-methoxyethyl 4-((4-(4-chlorophenoxy)-3,5-difluorophenyl)sulfonyl)-3-(hydroxycarbamoyl)piperazine-1-carboxylate Basic information

Product Name:
2-methoxyethyl 4-((4-(4-chlorophenoxy)-3,5-difluorophenyl)sulfonyl)-3-(hydroxycarbamoyl)piperazine-1-carboxylate
Synonyms:
  • 2-methoxyethyl 4-((4-(4-chlorophenoxy)-3,5-difluorophenyl)sulfonyl)-3-(hydroxycarbamoyl)piperazine-1-carboxylate
  • XL-784
  • XL 784,XL784
CAS:
1224964-36-6
MF:
C21H22ClF2N3O8S
MW:
549.9294864
Mol File:
1224964-36-6.mol
More
Less

2-methoxyethyl 4-((4-(4-chlorophenoxy)-3,5-difluorophenyl)sulfonyl)-3-(hydroxycarbamoyl)piperazine-1-carboxylate Chemical Properties

storage temp. 
Store at -20°C
solubility 
DMSO: ≥ 110 mg/mL (200.39 mM)
form 
Solid
color 
White to off-white
More
Less

2-methoxyethyl 4-((4-(4-chlorophenoxy)-3,5-difluorophenyl)sulfonyl)-3-(hydroxycarbamoyl)piperazine-1-carboxylate Usage And Synthesis

Uses

XL-784 is a selective matrix metalloproteinases (MMP) inhibitor, with IC50s of ~1900, 0.81, 120, 10.8, 18, 0.56 nM for MMP-1, MMP-2, MMP-3, MMP-8, MMP-9, MMP-13, respectively.

in vivo

All mice tolerate the treatments similarly. Control mice all developed aneurysms with a mean %△AD of 158.5%±4.3%. Treatment with all doses of XL-784 and doxycycline are effective in inhibiting aortic dilatation. There is a clear dose-response relationship between XL-784 and reductions in aortic dilatation at harvest (50 mg/kg 140.4% ±3.2%; 125 mg/kg 129.3% ±5.1%; 250 mg/kg 119.2%±3.5%; all Ps<0.01 compared to control). This continues with the higher doses (375 mg/kg 88.6%±4.4%; 500 mg/kg 76.0%±3.5%). The highest 2 doses of XL-784 tested are more effective than doxycycline (112.2%±2.0%, P<0.05) in inhibiting maximal dilatation of the aorta after elastase perfusion[2].

IC 50

MMP-2: 0.81 nM (IC50); MMP13: 0.56 nM (IC50); MMP-8: 10.8 nM (IC50); MMP-9: 18 nM (IC50); MMP-3: 120 nM (IC50); MMP-1: 1900 nM (IC50)

References

[1] Williams JM, et al. Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy. Am J Physiol Renal Physiol. 2011 Apr;300(4):F983-98. DOI:10.1152/ajprenal.00262.2010
[2] Ennis T, et al. Effect of novel limited-spectrum MMP inhibitor XL784 in abdominal aortic aneurysms. J Cardiovasc Pharmacol Ther. 2012 Dec;17(4):417-26. DOI:10.1177/1074248412455695

2-methoxyethyl 4-((4-(4-chlorophenoxy)-3,5-difluorophenyl)sulfonyl)-3-(hydroxycarbamoyl)piperazine-1-carboxylateSupplier

Suzhou Chukai PharmaTech
Tel
0512-88812066 15062531973;
Email
wenlongfcb@qq.com
TargetMol Chemicals Inc.
Tel
+1-781-999-5354; +17819995354
Email
marketing@targetmol.com
ChemeGen(Shanghai) Biotechnology Co.,Ltd.
Tel
18818260767
Email
sales@chemegen.com
cjbscvictory
Tel
13348960310
Email
3003867561@qq.com
TargetMol Chemicals Inc.
Tel
4008200310
Email
marketing@tsbiochem.com
More
Less

2-methoxyethyl 4-((4-(4-chlorophenoxy)-3,5-difluorophenyl)sulfonyl)-3-(hydroxycarbamoyl)piperazine-1-carboxylate(1224964-36-6)Related Product Information